[LCID Study Number: 2014-082]
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this study is to assess whether additional therapy with erlotinib will result in improved overall survival (OS) over observation for patients with completely resected stage IB non-small cell lung cancer following complete resection and standard post-operative therapy.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3071